Telix Pharmaceuticals (TLX) Common Equity (2023 - 2024)
Telix Pharmaceuticals (TLX) reported Common Equity of $371.6 million for Q4 2024, up 283.32% year-over-year from $96.9 million in Q1 2024, and up 283.32% quarter-over-quarter from $96.9 million in Q4 2023.
Telix Pharmaceuticals (TLX) Common Equity (2023 - 2024) Analysis & Trends
Telix Pharmaceuticals (TLX) has 2 years of Common Equity data on file, last reported at $371.6 million in Q4 2024.
- Common Equity for Q4 2024 came in at $371.6 million, up 283.32% year-over-year; the trailing twelve-month figure through Dec 2024 was $371.6 million (up 283.32% YoY), and the FY2024 annual result was $371.6 million, up 283.32% from the prior year.
- Common Equity grew to $371.6 million in Q4 2024 per TLX's latest filing, from $96.9 million in the prior quarter.
- Over five years, Common Equity peaked at $371.6 million in Q4 2024 and troughed at $96.9 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 35.63 Mn |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -1.42 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 14.38 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | 13.21 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 11.87 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 19.36 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Telix Pharmaceuticals | 4.43 Bn | 4.29 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 371.59 Mn |
| Dec 31, 2023 | 96.94 Mn |